An injection which is being considered a game changing obesity drug has just been approved for use in EU countries.
The European Medicines Agency (EMA) confirmed that the new drug called Wegovy has been green lit for use. It works by suppressing people’s appetites, leading to weight loss.
The EMA said that those who qualify for the jab will have ‘a BMI of 30 kg/m² or greater (obesity) or a BMI of at least 27 kg/m² but less than 30 kg/m² (overweight).’
People who have weight related health problems such as diabetes, high blood pressure, abnormal levels of fats in the blood, breathing problems during sleep called ‘obstructive sleep apnoea’ or a history of heart attacks, stroke or blood vessel problems will be eligible.
The jab would be injected once a week under the skin in the abdomen, thigh or upper arm. Only obtained via a prescription, the patients can administer the medicine themselves.
According to the EMA studies have shown that Wegovy is effective in helping people lose weight with a significant proportion of them achieving at least a 5% weight reduction.
As with every drug, the EMA highlighted that side effects are inevitable. Some of them include headaches, nausea, constitutions and even vomiting or diarrhoea. They may effect around 1 in 10 people.
#MaltaDaily